Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Administrative data

Description of key information

Benzyl salicylate was shown to be a skin sensitiser in a local lymph node assay according to OECD 429.

Key value for chemical safety assessment

Skin sensitisation

Link to relevant study records

Referenceopen allclose all

Endpoint:
skin sensitisation: in vivo (LLNA)
Type of information:
experimental study
Adequacy of study:
key study
Study period:
2004-05-19 to 2004-05-24 (positive control); 2004-07-21 to 2004-07-27 (main experiment)
Reliability:
1 (reliable without restriction)
Rationale for reliability incl. deficiencies:
guideline study
Qualifier:
according to guideline
Guideline:
OECD Guideline 429 (Skin Sensitisation: Local Lymph Node Assay)
Qualifier:
according to guideline
Guideline:
EPA OPPTS 870.2600 (Skin Sensitisation)
GLP compliance:
yes
Remarks:
no certificate
Type of study:
mouse local lymph node assay (LLNA)
Species:
mouse
Strain:
CBA
Sex:
female
Details on test animals and environmental conditions:
TEST ANIMALS
- Source: Harlan Interfauna Ltd, Blackthorne, Bicester, Oxon, United Kingdom
- Age at study initiation: Young adults (8 - 12 wks)
- Weight at study initiation: 16.8 g to 21.1 g
- Housing: ≤ 4 mice per cage, in suitable cages for this strain and weight range.
- Diet: Ad libitum RM1, Special Diet Services, Witham Essex, United Kingdom.
- Water: ad libitum mains water.
- Acclimation period: ≥ 5 d

ENVIRONMENTAL CONDITIONS
- Temperature: 22 °C ± 3 °C
- Humidity: 30 % to 70 %
- Air changes (per hr): ≥ 15
- Photoperiod: 12 hrs dark / 12 hrs light
Vehicle:
other: Ethanol:diethylphthalate (1:3)
Concentration:
2.5 % w/v, 5 % w/v, 10 % w/v, 25 % w/v and 50% w/v (No correction was made for the purity of the active ingredient of the test substance).
No. of animals per dose:
4 animals per dose
Details on study design:
TEST METHOD
Approximately 25 µL of preparation of the relevant concentration of test substance/vehicle was using a variable volume micropipette to the dorsal surface of each ear. A vehicle control group was similarly treated using vehicle alone. This procedure was repeated daily for 3 consecutive days.

3 d after the 3rd application, all the animals were injected, via the tail vein, with 250 µL of phosphate buffered saline (PBS) containing 25 µCi of a 2.0 Ci/mmol specific activity ³H-methyl thymidine. Approximately 5 hrs later, the animals were humanely killed by inhalation of halothene vapour followed by cervical dislocation. The draining auricular lymph nodes were removed from each animal and, together with the nodes from the other animals in the group, were placed in a container of PBS.

A single cell suspension was prepared by mechanical disintegration of lymph nodes through a 200-mesh stainless steel gauze. The cell suspensions were washed 3 times by centrifugation with approximately 10 mL of PBS. Approximately 3 mL of 5 % w/v trichloroacetic acid (TCA) was added and, after overnight precipitation at 4 °C, the samples were pelleted by centrifugation and the supernatant was discarded. The cells were then resuspended in approximately 1 mL of TCA.

The lymph node suspensions were transferred to scintillation vials and 10 mL of scintillant (Octiphase) was added prior to β-scintillation using a Packard Tri-Car Liquid scintillation counter.

Animals were checked at least daily for signs of systemic toxicity.
Positive control substance(s):
hexyl cinnamic aldehyde (CAS No 101-86-0)
Statistics:
The EC₃ value was derived by interpolating between two points on the stimulation index axis, using values immediately above and below the value of 3. The equation is as follows:

EC₃ = (3 - d) × (a - c) ÷ (b - d) + c

Where:
a = The concentration giving the SI immediately above 3
b = The SI value of a
c = The concentration giving the SI immediately below 3
d = The SI value of c

From this value a value of quantity applied per square centimetre was derived, assuming that the area of the mouse ear is 1 cm² and that 1 µL is equivalent to 1 mg.
Parameter:
other: disintegrations per minute (DPM)
Remarks on result:
other: 0 % (vehicle control) - 2248 DPM; 2.5 % - 5728 DPM; 5 % - 12419 DPM; 10 % - 13518 DPM; 25 % - 42548 DPM; 50 % - 58830 DPM. For full results table please refer to the attached supporting information.
Parameter:
EC3
Value:
2.9
Parameter:
SI
Value:
2.6
Test group / Remarks:
2.5%
Parameter:
SI
Value:
5.5
Test group / Remarks:
5%
Parameter:
SI
Value:
6
Test group / Remarks:
10%
Parameter:
SI
Value:
18.9
Test group / Remarks:
25%
Parameter:
SI
Value:
26.2
Test group / Remarks:
50%

Evaluation of the test substance

The EC₃ value was derived as described above and determined to be 2.9 %

From this, the quantity applied per square centimetre was determined to be 725 µg/cm.

Body weights

Information on body weights is given in the attached supporting information.

Positive control

The application of hexylcinnamaldehyde at concentrations of 5 %, 10 % and 25 % w/v in acetone:olive oil (4:1) resulted in a greater than threefold increase in isotope incorporation at both 10 % and 25 %. Thus, hexylcinnamaldehyde was shown to be a potential skin sensitiser under the conditions of the test.

Interpretation of results:
sensitising
Remarks:
Migrated information Criteria used for interpretation of results: EU
Conclusions:
Benzyl salicylate was shown to be a skin sensitiser in a local lymph node assay according to OECD 429.
Endpoint:
skin sensitisation: in vitro
Data waiving:
study scientifically not necessary / other information available
Justification for data waiving:
an in vitro skin sensitisation study does not need to be conducted because adequate data from an in vivo skin sensitisation study are available
Endpoint conclusion
Endpoint conclusion:
adverse effect observed (sensitising)
Additional information:

Benzyl salicylate was shown to be a skin sensitiser in a local lymph node assay according to OECD 429.


Respiratory sensitisation

Endpoint conclusion
Endpoint conclusion:
no study available

Justification for classification or non-classification

Benzyl salicylate was shown not to be a skin sensitiser in a local lymph node assay according to OECD 429. The EC₃ value was triggered at test concentration of 2.9 %, thus classification as a skin sensitiser Cat 1B is required according to the (EC) No1272/2008 Regulation (CLP).